|
LIVE WEBINAR: Thursday, May 8, 2025 | 5:00 PM – 6:00 PM Eastern Time (ET)
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oncology A Multitumor CME/MOC-Accredited Live Webinar Series
Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page. Join us on Thursday, May 8th for this CME/MOC-accredited webinar Faculty
Meletios-Athanasios (Thanos) C Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece Robert Z Orlowski, MD, PhD Florence Maude Thomas Cancer Research Professor Department of Lymphoma and Myeloma Professor, Department of Experimental Therapeutics Vice Chair, Myeloma Translational Research Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas
Moderator
Neil Love, MD Research To Practice Miami, Florida Thursday, May 8, 2025 Topics to be announced. Target Audience Learning Objectives CE Credit Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Privacy Policy Unlabeled/Unapproved Uses Notice Content Validation and Disclosures FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Prof Dimopoulos — Advisory Committees, Consulting Agreements and Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma SA, Takeda Pharmaceutical Company Limited. Dr Orlowski — Advisory Committees and Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Asylia Therapeutics Inc, Biotheryx, Bristol Myers Squibb, CellCentric, DEM BioPharma, IASO Bio, Karyopharm Therapeutics, Lytica Therapeutics, Meridian Therapeutics, Monte Rosa Therapeutics, MYELOMA360, Neoleukin Therapeutics Inc, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |